Related Experiment Video
Updated: Jul 28, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
OnabotulinumtoxinA for Pediatric Migraine
Victoria Karian1, Hannah Morton1, Zoë J Schefter1
1Pediatric Headache Program, Division of Pain Medicine, Department of Anesthesiology, Perioperative & Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.
Insights
OnabotulinumtoxinA (BTX-A) effectively reduced headache frequency and severity in pediatric patients with chronic migraine. This treatment offers a safe option for children, improving their quality of life.
Area of Science:
- Pediatric Neurology
- Clinical Therapeutics
- Pain Management
Background:
- Migraine significantly impacts children's well-being, necessitating safe and effective treatments.
- Access to appropriate therapies is crucial for managing this chronic condition in pediatric populations.
Purpose of the Study:
- To evaluate the experiences, effects, and clinical response of adolescents to onabotulinumtoxinA (BTX-A) for migraine prevention.
- To assess the safety and efficacy of BTX-A in managing chronic migraine in children aged 13-17.
Main Methods:
- Retrospective review of clinical data for 32 pediatric patients (13-17 years) treated with BTX-A for chronic migraine (2016-2022).
- Analysis of variance (ANOVA) used to compare headache frequency, severity, and duration at baseline and after BTX-A injections.
Main Results:
- BTX-A treatment led to a significant decrease in headache frequency and severity.
- Participants experienced approximately seven fewer headache days per month post-treatment.
- Reported side effects included neck stiffness, flu-like symptoms, fatigue, and temporary pain worsening.
Conclusions:
- OnabotulinumtoxinA (BTX-A) is a safe and effective treatment option for pediatric migraine.
- BTX-A can significantly reduce the burden of chronic migraine on children's physical, emotional, and mental health.
- Nurses play a vital role in advocating for and educating patients about BTX-A for pediatric migraine management.
Background:
Migraine is a painful, prevalent, and problematic condition among children. Children need access to safe and effective treatment options to alleviate the impact of this chronic condition on their wellbeing.
Clinical Implications:
Nurses have a crucial role in supporting patient access to BTX-A. Given the results of this and other studies demonstrating the safety and efficacy of BTX-A in children, nurses can support policy change for health plans to fund this intervention for pediatric migraineurs. Allowing children to receive the safe and effective BTX-A injections will lessen the already significant impact of chronic migraine on their physical, emotional and mental health. Nurses can also play a key role in providing education to patients regarding safe administration of BTX-A for migraine.
Aim:
The objective of this study was to define the experiences, effects, and clinical response of children to onabotulinumtoxinA (BTX-A) for migraine prevention.
Methods:
Clinical documentation for patients aged 13-17 years presenting for BTX-A treatment for chronic migraine between 2016-2022 in a community-based specialty clinic within a large, urban, pediatric academic medical center were included. A series of one-way repeated measures (analysis of variance [ANOVA]) were conducted to compare headache frequency, severity, and duration at baseline, and following first and second injections of BTX-A.
Results:
Of 32 eligible participants, administration of BTX-A demonstrated a decrease in headache frequency and severity. Participants reported nearly seven fewer headache days per month. Participants reported neck stiffness, fever or flu-like symptoms, fatigue, and worsening pain following BTX-A administration.
Conclusions:
Pediatric migraineurs need therapies that are safe, effective, and accessible. BTX-A was a safe and effective treatment for migraine among the children included in this study.
More Related Videos
Related Concept Videos
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drug Dosing: Infants and Children
Botulism

